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Professions, Marshall University, Huntington, WV, USAA B S T R A C TBackground: Metformin is the ﬁrst-line oral hypoglycemic agent for
type 2 diabetes mellitus (T2DM) per international guidelines with proven
efﬁcacy, safety, and cost-effectiveness. However, little information
comparing it with acarbose exists. Objective: To study the cost-
effectiveness of metformin and acarbose—two extensively adopted
agents—in treating T2DM. Methods: Cost-minimization analysis was
conducted on the assumption that metformin and acarbose have
equivalent clinical effectiveness. The cost of treatment was detected
and evaluated from a payer’s perspective. In sensitivity analyses, several
clinical scenarios were developed according to clinical practices and
physicians’ prescribing behaviors in China. Results: Metformin can save
annual treatment costs by 39.87% to 40.97% compared with acarbose.ee front matter Copyright & 2015, International S
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ngtang Road, Hangzhou, Zhejiang 310058, China.Under a wide range of assumptions on utilization proﬁle and physician
prescribing behavior, it saves costs by 19.83% to 40.97% in patients
whose weight is 60 kg or less and by 39.87% to 70.49% in patients whose
weight is more than 60 kg, which corroborates the results that metfor-
min is more cost-effective than acarbose. Conclusions: Metformin
appears to provide better value for money than does acarbose. Findings
from this study are consistent with those from previous studies that
metformin is undoubtedly the ﬁrst choice in the management of T2DM,
with signiﬁcant glucose-lowering effects and low treatment costs.
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Diabetes is one of the common chronic diseases worldwide [1].
China leads among the countries with the highest prevalence of
diabetes. In 2010, the prevalence of diabetes in Chinese adults 18
years and older was 11.6% (113.9 million) [2]. Because of the long
duration and expensive treatment, diabetes not only affects
patients’ quality of life but also brings a heavy economic burden
to both the family and the society. A study on the epidemic and
economic burden of diabetes in China [3] indicates that the
average annual growth rate of direct medical cost of diabetes
was 19.9% in recent years, which was higher than the gross
domestic product and national health care expenditure growth
over the same period, ranking the second in all surveyed chronic
diseases.
Type 2 diabetes mellitus (T2DM) accounts for at least 90% of all
cases of diabetes [4]. It has brought great burden in terms of health
care cost and socioeconomic consequences, reaching $26.0 billion
in 2007 in direct medical costs and predicted to be $47.2 billion by
2030 in China [5]. Glycemic control in patients with T2DM isdirectly related to the occurrence of diabetes-related complications
and the extent of damage to target organs, and it is the key point
in treating T2DM. When lifestyle interventions can no longer bring
about glycemic control, oral hypoglycemic agents are the main
methods used for the treatment of T2DM. Owing to the advances
in T2DM treatment, there are many kinds of oral hypoglycemic
agents available in the market. Each agent has its peculiarity in
mechanism and site of action; thus, their glucose-lowering effects
and treatment costs for patients vary signiﬁcantly.
As a biguanide drug, metformin is the ﬁrst-line oral hypogly-
cemic agent for T2DM in compliance with international guide-
lines with proven efﬁcacy, safety, and cost-effectiveness [6–8],
whereas acarbose, one of the α-glucosidase inhibitors, is recom-
mended as one of the second-line drugs in the treatment of
diabetes in China [7]. In use of oral antidiabetic drugs in China,
metformin (53.7%) and α-glucosidase inhibitors (including acar-
bose, 35.9%), however, are both widely accepted and used either
as monotherapy or in combination with other antidiabetic agents
[9]. A possible reason for the popular use of acarbose may be its
effect, which is superior in patients eating a relatively highociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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however, comparing metformin with acarbose in both clinical
effectiveness and cost-effectiveness.
After a meta-analysis, it was found that glucose-lowering
effects of metformin monotherapy and acarbose monotherapy
are the same by direct comparison, while metformin monother-
apy is a little better by indirect comparison [11]. This means that
glucose-lowering effects of metformin monotherapy are at least
as good as those of acarbose monotherapy. Thus, this study
aimed to make an economic evaluation by using a cost-
minimization analysis technique to see which drug is more
cost-effective.Methods
Estimation of the Cost
The perspective of the payer was used in this study because both
drugs are covered by the payer. Cost was estimated on the basis
of treatment schedules from the literature [12–19] and prices of
both drugs in China; only direct medical costs were included. For
metformin (brand name Glucophage, speciﬁcation 500 mg  20
tablets), the highest price set by the government is ¥29.2 and the
lowest set by the market is ¥24.82; for acarbose (brand name
Glucobay, speciﬁcation 50 mg  30 tablets), the highest and the
lowest price is ¥74.2 and ¥61.92, respectively [20–23]. Both the
lowest and highest prices were used to estimate the annual
average treatment cost. Because both drugs are common oral
hypoglycemic agents and tolerated well and have similar treat-
ment efﬁcacy and gastrointestinal adverse reactions, which can
be alleviated by starting at a low dose and escalating the dose
gradually [7,11,24–26], we, therefore, assume that patients taking
both drugs have the similar frequency of doctor visits. Thus, we
assume that the relevant costs in treating T2DM, such as doctor
visit, diagnostic, inspection, and hospitalization cost, and so forth
[27], can be set to be equivalent and not included in this study. All
costs were based on 2014 prices and expressed in Renminbi (¥).
No cost discounting was applied because all costs were measured
by a period of 1 year.
Base-Case Identiﬁcation
There is no ﬁxed dosage regimen for the management of hyper-
glycemia in patients with T2DM with metformin or acarbose or
any other pharmacologic agents [24,25]. Data on medication use
and average dosage were derived from the direct comparison
section of the meta-analysis [11–19], which directly compared the
treatment effect of metformin and acarbose and showed their
comparable efﬁcacy in the Chinese population (1500 mg/d for
metformin and 150 mg/d for acarbose).
Sensitivity Analysis
Because physicians’ compliance with drug’s instruction recom-
mendations or national guidelines with regard to the initiation
and monitoring of drug dosage in treating T2DM is unknown, in
sensitivity analysis, several different clinical scenarios were
developed after interviews with physicians treating diabetic
patients, to illustrate potential clinical situations as well as to
analyze the difference in annual average treatment costs with
metformin and acarbose.
Based on physicians’ prescribing behaviors in China and the
potential increased risk for elevated serum transaminases in
patients with low body weight [25], the usual maximum dose of
acarbose is slightly different in different weight groups (150 mg/d
for weight r 60 kg and 300 mg/d for weight 4 60 kg) [28–30].
Meanwhile, because of the difference in clinical prescribinghabits and cognition of physicians in China, metformin also
has two usual maximum doses (1500 and 2000 mg/d) in clinical
practice, which is not strongly associated with patients’ weight.
Eight clinical scenarios, therefore, were developed according to
different therapeutic regimens for patients with T2DM with
different body weights to model different clinical conditions that
may reﬂect real-world usage patterns of patients with T2DM.
Scenario 1 considered all patients treated using only one oral
drug (metformin or acarbose) at the initial dose. Scenarios 2, 5,
and 6 involved patients who received only one oral drug (met-
formin or acarbose) at the usual maximum dose. Scenarios 3, 4, 7,
and 8 simulated a situation that both drugs were titrated from
the initial dose to the usual maximum dose gradually in patients
with different body weights (Table 1). The common character-
istics of scenarios 2 to 4 are that patients’ weight is 60 kg or less
and that of scenarios 5 to 8 is that patients’ weight is more than
60 kg. Moreover, scenario 1 includes both weight groups (Table 1).Results
Annual Average Treatment Cost of Metformin and Acarbose
at Base Case
In base-case cost analysis, the annual treatment cost of metfor-
min was ¥1358.90 while that of acarbose was ¥2260.08 when
referring to the lowest price; the annual treatment cost of
metformin and acarbose was ¥1598.70 and ¥2708.30 referring to
the highest price, respectively. Under the same level of glycemic
control, metformin could achieve annual cost savings by 39.87%
(lowest price) or 40.97% (highest price) compared with acarbose
(Table 2).
Annual Average Treatment Cost of Metformin and Acarbose
at Different Scenarios
The annual treatment cost of metformin ranged from ¥452.97 to
¥2131.60 whereas that of acarbose ranged from ¥753.36 to
¥2708.30 at the four different scenarios (scenarios 1–4) in which
patients’ weight is 60 kg or less. Under these assumptions,
metformin also minimizes the cost in all the four scenarios
regardless of changes in daily dosage or medication cost, remain-
ing a cost-saving strategy of 19.83% to 40.97% (Table 2).
The annual treatment cost of metformin ranged from ¥452.97
to ¥2131.60 whereas that of acarbose ranged from ¥753.36 to
¥5416.60 at the ﬁve different scenarios (scenario 1, and 5–8) in
which patients’ weight is more than 60 kg. For all the ﬁve
scenarios, metformin administration was the lower cost strategy
compared with acarbose, for which savings ranged from 39.87%
to 70.49% (Table 2).Discussion
Economic evaluation refers to the comparative analysis of alter-
native projects in terms of their costs and consequences by using
principles and methods of economics. In the context of current
health policy, with more and more governments trying to limit
the escalation in health expenditure, there is an increasing need
to ﬁnd medical treatment strategies that are as effective but less
costly. A pharmacoeconomic approach is commonly used to
evaluate the health beneﬁt of drug treatments to gain good value
for money. Economic evaluation of medical products is partic-
ularly important in a country such as China, where for the
inclusion of a drug in the national essential drugs list, the call
in and out of a drug in the National Reimbursement Drug List,
and the pricing of new drugs, patent medicines, and other drugs,
Table 1 – Clinical scenarios for patients with T2DM with different body weight.
Scenario Patient Description
1 All weights Metformin is maintained in initial dose (500 mg/d); acarbose is maintained in initial dose (50 mg/d).
2 Weight r 60 kg Metformin is maintained in usual maximum dose (2000 mg/d, given in divided doses); acarbose is
maintained in usual maximum dose (150 mg/d, given in divided doses).
3 Weight r 60 kg Metformin is started at 500 mg/d for the ﬁrst week and titrated up to 1000 mg/d given in divided doses
in the second week and to 1500 mg/d given in divided doses from the third week onwards.
Acarbose is started from 50 mg/d during the ﬁrst week and titrated up to 100 mg/d given in divided
doses in the second week and to 150 mg/d given in divided doses from the third week onwards.
4 Weight r 60 kg Metformin is started at 500 mg/d for the ﬁrst week and titrated up to 1000 mg/d given in divided doses
in the second week, to 1500 mg/d given in divided doses in the third week, and to 2000 mg/d given
in divided doses from the fourth week onwards.
Acarbose is started from 50 mg/d during the ﬁrst week and titrated up to 100 mg/d given in divided
doses in the second week and to 150 mg/d given in divided doses from the third week onwards.
5 Weight 4 60 kg Metformin is maintained in usual maximum dose (1500 mg/d, given in divided doses); acarbose is
maintained in usual maximum dose (300 mg/d, given in divided doses).
6 Weight 4 60kg Metformin is maintained in usual maximum dose (2000 mg/d, given in divided doses); acarbose is
maintained in usual maximum dose (300 mg/d, given in divided doses).
7 Weight 4 60kg Metformin is started at 500 mg/d for the ﬁrst week and titrated up to 1000 mg/d given in divided doses
in the second week and to 1500 mg/d given in divided doses from the third week onwards.
Acarbose is started from 50 mg/d during the ﬁrst week and titrated up to 100 mg/d given in divided
doses in the second week, to 150 mg/d given in divided doses in the third week, and to 300 mg/d
from the fourth week onwards.
8 Weight 4 60 kg Metformin is started at 500 mg/d for the ﬁrst week and titrated up to 1000 mg/d given in divided doses
in the second week, to 1500 mg/d given in divided doses in the third week, and to 2000 mg/d given
in divided doses from the fourth week onwards.
Acarbose is started from 50 mg/d during the ﬁrst week and titrated up to 100 mg/d given in divided
doses in the second week, to 150 mg/d given in divided doses in the third week, and to 300 mg/d
from the fourth week onwards.
T2DM, type 2 diabetes mellitus.
Table 2 – The annual treatment cost of metformin and acarbose in patients with T2DM.
Scenario Price* Annual treatment cost (¥) Cost difference (¥)† Saving in annual cost (%)‡
Acarbose Metformin
Base case Lowest 2260.08 1358.90 901.18 39.87
Highest 2708.30 1598.70 1109.6 40.97
Patients with T2DM with weight r 60 kg
Scenario 1 Lowest 753.36 452.97 300.39 39.87
Highest 902.77 532.90 369.87 40.97
Scenario 2 Lowest 2260.08 1811.86 448.22 19.83
Highest 2708.30 2131.60 576.7 21.29
Scenario 3 Lowest 2216.74 1332.83 883.91 39.87
Highest 2656.36 1568.04 1088.32 40.97
Scenario 4 Lowest 2216.74 1759.74 457 20.62
Highest 2656.36 2070.28 586.08 22.06
Patients with T2DM with weight 4 60 kg
Scenario 1 Lowest 753.36 452.97 300.39 39.87
Highest 902.77 532.90 369.87 40.97
Scenario 5 Lowest 4520.16 1358.90 3161.26 69.94
Highest 5416.60 1598.70 3817.9 70.49
Scenario 6 Lowest 4520.16 1811.86 2708.3 59.92
Highest 5416.60 2131.60 3285 60.65
Scenario 7 Lowest 4346.78 1332.83 3013.95 69.34
Highest 5208.84 1568.04 3640.8 69.90
Scenario 8 Lowest 4346.78 1759.74 2587.04 59.52
Highest 5208.84 2070.28 3138.56 60.25
T2DM, type 2 diabetes mellitus.
* Lowest, the lowest set by market; highest, the highest price set by government.
† Cost difference ¼ annual cost of acarbose  annual cost of metformin.
‡ Saving in annual cost ¼ (annual cost of acarbose  annual cost of metformin)  100/annual cost of acarbose.
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drugs be conducted by using evidence-based medicine and
pharmacoeconomics approaches [31–34].
This study examined the costs of metformin and acarbose in
the treatment of patients with T2DM. We used the cost-
minimization analysis technique under the hypotheses that key
clinical outcomes and adverse effects of both drugs are effectively
equivalent based on results from a previous meta-analysis study
[11]. Our results show that metformin seems to be more cost-
effective than acarbose.
In economic evaluation, it is difﬁcult to accurately measure
the study variables, and each medication therapy may bring
different treatment costs when applied among different popula-
tion or medical institutions; therefore, it is important to verify the
effect of basic assumptions on study results. Thus, we developed
eight scenarios, in sensitivity analyses, to mirror the real-life cost
proﬁle. The results are consistent with the base-case analysis,
corroborating that metformin is more cost-effective than acar-
bose. Our results, however, may represent a cost-effective
advantage for metformin only if differences in dosage adjust-
ment and monitoring were observed in a real clinical practice and
underlying hypotheses mentioned above are true.
Results from this study conﬁrm ﬁndings from several eco-
nomic evaluation studies conducted in China, comparing met-
formin monotherapy with acarbose monotherapy in the
treatment of T2DM. The studies reported that metformin was
cost-effective than acarbose for treating T2DM [35–41], and
particularly, it was superior to acarbose in controlling fasting
blood glucose [42–46]. As the course of T2DM prolongs, any single
therapy may ﬁnd it difﬁcult to effectively control the blood
glucose level of patients with T2DM, and then there is a need
to use combination therapies to strengthen glycemic control in
clinical practice. In this context, several studies assessing the
comparative efﬁcacy and cost of metformin and acarbose from
the perspective of drug combination also indicate that metformin
combination therapy is still a preferable therapeutic regimen
compared with acarbose combination therapy [47–50]. Never-
theless, the reliability of these evaluation results might be con-
strained attributable to small sample sizes (range 87–705) in their
basal clinical trials; thus, these ﬁndings should be considered
with caution. Furthermore, a review of the economic evaluation
of metformin hydrochloride and acarbose suggests that they
have a similar role in prolonging the life of patients, improving
the cardiovascular disease, and preventing or delaying the onset
of T2DM [51]. Metformin hydrochloride is a preferred treatment
for patients with T2DM, with a higher efﬁciency in reducing
fasting blood glucose and minimum cost compared with other
hypoglycemic drugs. Although acarbose is good at reducing
postprandial blood glucose, it has a higher cost [51]. Moreover,
in patients with impaired glucose tolerance, metformin demon-
strates a better value for money [51]. Metformin is more cost-
effective not only in treating T2DM but also in preventing the
onset of diabetes compared with acarbose [52,53].
This study was conducted from a payer’s perspective, and the
indirect cost related to the T2DM treatment was not taken into
account. Direct medical costs theoretically consist of fees for
doctor visit, medication cost, diagnostic cost, inspection cost,
hospitalization cost, transport cost, and so forth [27]. However, in
this study, we estimated only the drug cost, not other costs
because we assumed that other costs are the same in the two
treatment groups. This study, furthermore, considers only a
single monotherapy for 1 year; however, in clinical practice,
because of the complexity of diabetes, drug combination therapy
is common and patients may switch drugs, which can have an
impact on the cost; over a longer period, more complications
related to diabetes, including microvascular and macrovascular
disease, may occur [6], which can also add treatment costs. Thus,more studies are needed to understand the comprehensive
annual costs to provide disease burden information for guiding
decision making of resource allocation.
Regardless of these limitations, our study has a noteworthy
strength that it is the ﬁrst economic evaluation focusing on the
comparison of metformin with acarbose in T2DM treatment,
which is conducted on the basis of results from a meta-analysis
study with large sample sizes and adequate clinical data.Conclusions
Metformin appears to provide better value for money than does
acarbose. Findings from this study are consistent with previous
studies that metformin is undoubtedly the ﬁrst choice in the
management of T2DM, with signiﬁcantly glucose-lowering effects
and low treatment costs.Acknowledgments
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